Navigation Links
InterMune to Present at BMO Healthcare Conference
Date:7/30/2008

BRISBANE, Calif., July 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the BMO Capital Markets 2008 Focus on Healthcare Conference in New York on August 6, 2008 at 10:00 a.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
2. InterMune to Present at Jefferies Healthcare Conference
3. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
4. InterMune to Present at Citigroup Healthcare Conference
5. InterMune to Present at Bank of America Health Care Conference
6. InterMune to Present at Deutsche Bank Health Care Conference
7. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
8. Evotec Expands Collaboration With InterMune
9. InterMune to Present at the SIGnificant Options in Healthcare Conference
10. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
11. InterMune Announces Closing of Public Offering of Common Stock

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2009)...LLE, Ala., Nov. 4 DIATHERIX Labora...today presented at the Michigan Security Network H...earborn, Mich. Dennis Grimaud, Chairman and Chief ...ct of the company,s advanced molecular diagnostic ...fectious disease diagnosis and military efforts. ...
(Date:11/4/2009)..., ROCKVILLE, Md., Nov. 4 Zyngenia...ocused on next-generation antibody drug developmen... in Series A funding from New Enterprise Associate...l firms. The capital will be used to create novel,...ss two or more biological targets with a single ag...
(Date:11/4/2009)...LOS, Calif., Nov. 4 Nekt...s financial results for the third quarter ended Se...ended September 30, 2009 improved to $31.0 million...$37.0 million or $0.40 per share in the third quar...rovements to its operating efficiencies as compare...
(Date:11/4/2009)...CITY, Nov. 4 /PRNewswire-FirstCall/ - Medicago Inc... developing highly effective and affordable vaccin... and Virus-Like Particles (VLPs), today announced ...tment of Health and Human Services (HHS) to presen...p (GHSI) on November 5, 2009 at 2:40 pm (EST) at t...
Breaking Biology Technology:DIATHERIX Laboratories Presents at Homeland Security Conference 2Zyngenia, Inc. Raises $10 Million in Series A Funding 2Zyngenia, Inc. Raises $10 Million in Series A Funding 3Zyngenia, Inc. Raises $10 Million in Series A Funding 4Nektar Therapeutics Reports Third Quarter 2009 Financial Results 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 3Nektar Therapeutics Reports Third Quarter 2009 Financial Results 4Nektar Therapeutics Reports Third Quarter 2009 Financial Results 5Nektar Therapeutics Reports Third Quarter 2009 Financial Results 6Nektar Therapeutics Reports Third Quarter 2009 Financial Results 7Nektar Therapeutics Reports Third Quarter 2009 Financial Results 8Nektar Therapeutics Reports Third Quarter 2009 Financial Results 9Nektar Therapeutics Reports Third Quarter 2009 Financial Results 10Medicago to present at the U.S. Department of Health and Human Services' Global Health Security Initiative Workshop 2
...ogics platform for robust growth -, - Includes pr...rocessing facility -...n 2008 and $25 million in 2009; no dilution to e... in-process R&D charge -, SAN DI...al device company focused on developing products f...
...May 8 Pharmos Corporation,(Nasdaq: PARS ) today ... 31,2008. The Company recorded a net loss of $3.6 ...2008 compared to a net loss of $4.8 million, or $0... short-term investments,totaled $11.3 million at M...first quarter 2008 is due primarily to,a 29% decre...
..., May 8 Edwards Lifesciences,Corporation (NYSE: ...ves,announced that the company will celebrate a nu...uts at the 88th annual meeting of the American,Ass... San Diego., Among the milestones marked by Edwar...ary of partnering with clinicians to develop life-...
Other Biology Technology:NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics 2NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics 3NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics 4NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics 5NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics 6Pharmos Corporation Reports 2008 First Quarter Results 2Pharmos Corporation Reports 2008 First Quarter Results 3Pharmos Corporation Reports 2008 First Quarter Results 4Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008 2Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008 3Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008 4
(Date:11/5/2009)...ion of Biology Teachers (NABT) will recognize Leon... at Naugatuck Valley Community College (NVCC) in W...cation Award during the NABT annual professional d...09 in Denver, Colorado. , The Evolution Educatio...f Biological Sciences,(AIBS) and Biological Scien...
(Date:11/4/2009)...n natural science) , United States Using Less ... today than it did 35 years ago, despite a 30 perc... partly attributable to alternative cooling method...stems. According to the latest USGS water use repo...ates goes to cooling thermoelectric power plants. ...
(Date:11/4/2009)...ory that deciphered the DNA codes, or genomes, of ... has joined The Genome 10K Project, an internation... sequences on 10,000 species of animals for conduc... can not be achieved. , Participating in The Gen... the Nov. 5, 2009 issue of the Journal of Heredit...
Breaking Biology News(10 mins):Biologists, educators recognize excellence in evolution education 2USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7Singapore scientists join international study of 10,000 vertebrates' genomes 2HowStuffWorks com Campaign Proves Determination and Curiosity More Powerful than Gravity 52421 1HowStuffWorks com Campaign Proves Determination and Curiosity More Powerful than Gravity 52421 2HowStuffWorks com Campaign Proves Determination and Curiosity More Powerful than Gravity 52421 3Two Years Remain for Physicians to Obtain Sleep Medicine Certification without Fellowship Training 52419 1Two Years Remain for Physicians to Obtain Sleep Medicine Certification without Fellowship Training 52419 2Two Years Remain for Physicians to Obtain Sleep Medicine Certification without Fellowship Training 52419 3Two Years Remain for Physicians to Obtain Sleep Medicine Certification without Fellowship Training 52419 4Genstar Capital Portfolio Company Univita Health Completes Debt Financing 52417 1Genstar Capital Portfolio Company Univita Health Completes Debt Financing 52417 2Genstar Capital Portfolio Company Univita Health Completes Debt Financing 52417 3
...vider Deploys Biometric Access Control Solution, ...ds, WALL, N.J., Sept. 30 BIO-key International,I...ss public safety,solutions and finger-based biomet...andolph ("Parente"), a leading accounting and cons...tity solution to secure their new,headquarters., ...
...roup led by Prof Makoto Tominaga and Dr Takaaki So...s (NIPS), Japan, found that a small fly, drosophil...roup reports their finding in Journal of Neurosci...nown how flies detect a noxious heat to avoid it. ...ainless" protein, which had been known to be impor...
...Federation of American Scientists (FAS) will reach...gically accurate immunology video game through a g.... This bold and fun game is available for download...o release the next version of Immune Attack in Feb... for the FAS Learning Technologies Program. "We,r...
Other Biology News:Parente Randolph Secures Access to New Corporate Headquarters With BIO-key(R) Biometric Identification 2Parente Randolph Secures Access to New Corporate Headquarters With BIO-key(R) Biometric Identification 3Entertainment Software Association Foundation awards grant to FAS for immune attack 2
Mouse Anti-Macrophage L1 protein Calprotectin Monoclonal Antibody, Unconjugated, Clone B314.1 (MAC 387) from Abcam
Mouse Anti-Human CYTOKERATIN 1-8 Monoclonal Antibody, Unconjugated, Clone Ks1-8 from AbD Serotec
Human Mesenchymal Stem Cell Functional Identification Kit from R&D Systems
BRIJ 35 - 1 Gallon from GeneTex
Biology Products: